哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-049 哈尔滨誉衡药业股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、2024 年 1 月 15 日，公司第六届董事会第十一次会议、第六届监事会第 九次会议审议通过了《关于<2024 年限制性股票激励计划（草案）>及其摘要的 议案》等相关议案。 2、2024 年 1 月 16 日至 2024 年 1 月 25 日，公司在公司官方网站公示了拟 激励对象的姓名和职务，截至公示期满，公司监事会未收到任何对本次激励对象 第 1 页 哈尔滨誉衡药业股份有限公司 1、哈尔滨誉衡药业股份有限公司（以下简称"公司"）2024 年限制性股票 激励计划首次授予部分第一个限售期解除限售条件已经成就，本次符合解除限售 条件的激励对象共计 95 人，可解除限售的限制性股票数量为 27,997,600 股，约 占公司目前总股本的 1.2467%。 2、本次解除限售的限制 ...

Core Viewpoint - Yuheng Pharmaceutical has demonstrated outstanding performance in a relatively sluggish pharmaceutical industry, achieving significant growth in core products and cost reduction efforts, with a notable increase in net profit and cash flow in 2024 and Q1 2025 [1][2][7] Financial Performance - In 2024, the company's net profit attributable to shareholders increased by 93.43% year-on-year, reaching 233 million yuan, while the net profit excluding non-recurring items surged by 243.42% to 183 million yuan [1] - For Q1 2025, the net profit attributable to shareholders and net profit excluding non-recurring items grew by 15.24% and 54.74% year-on-year, amounting to approximately 60.25 million yuan and 49.73 million yuan, respectively [1] - The operating cash flow increased by 49.88% year-on-year to 411 million yuan, and the weighted average return on equity rose to 12.89%, up 5.63 percentage points [2] - The basic earnings per share increased by 93.60% to 0.1059 yuan/share in 2024, with a further 16.60% growth in Q1 2025, reaching 0.0274 yuan/share [2] Asset Quality Improvement - By the end of 2024, the net assets attributable to shareholders grew by 17.39% year-on-year to approximately 1.951 billion yuan, while the debt-to-asset ratio decreased by 15.58 percentage points to 30.17%, the lowest level in a decade [2] - The company’s operational efficiency improved, with current asset turnover increasing from 1.77 times to 2.40 times, and total asset turnover rising from 0.73 times to 0.82 times [3] Sales Efficiency and Cost Management - In 2024, the company enhanced sales efficiency through organizational adjustments and process management, resulting in a 25.82% decrease in sales expenses, with the sales expense ratio falling to 32.48% [3] - Management expenses and financial costs also saw significant reductions, with management expenses down 18.29% and financial expenses down 103.41% in 2024 [3] Product Development and Innovation - The company has maintained a "Product First" strategy, expanding its product line from orthopedics to major therapeutic areas such as cardiovascular and cerebrovascular diseases, with several core products experiencing rapid sales growth [4] - In 2024, sales of the exclusive traditional Chinese medicine product An Nao Wan/Pian grew over 90%, while the injection of multiple vitamins maintained an 80% market share with a 40% sales increase [4] - The company has a robust pipeline of over 20 projects, with several products receiving drug approval numbers and others undergoing consistency evaluations [6] Strategic Partnerships - Yuheng Pharmaceutical has strengthened its collaboration with the global pharmaceutical company Daiichi Sankyo, signing promotional agreements for new products, which are expected to contribute positively to the company's performance [5][6] Market Confidence and Shareholder Engagement - The company launched an equity incentive plan covering over 100 key personnel and implemented a share repurchase plan, reflecting confidence in its future development [6] - Major shareholders have collectively increased their holdings by nearly 30 million shares, indicating strong market confidence in the company's long-term value proposition [6][7]

Financial Performance - In 2024, the company's operating revenue was 2.441 billion CNY, a year-on-year decrease of 7.06% [1] - Net profit attributable to shareholders was 233 million CNY, an increase of 93.43% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 183 million CNY, up 243.42% year-on-year [1] - Operating cash flow increased by 4.11% to 498 million CNY [1] - The weighted average return on equity rose to 12.89%, an increase of 5.63 percentage points year-on-year [1] Revenue Composition By Industry - Chemical drugs accounted for 2.254 billion CNY, 92.33% of total revenue [2] - Traditional Chinese medicine (mainly An Nao Wan/Pian) generated 182 million CNY, 7.46% [2] - Other industries contributed 502.38 thousand CNY, 0.21% [2] By Product - Vitamin drugs generated 1.125 billion CNY, 46.10% of total revenue [3] - Cardiovascular drugs brought in 670 million CNY, 27.43% [3] - Orthopedic drugs accounted for 272 million CNY, 11.13% [3] - Antitumor drugs generated 129 million CNY, 5.28% [3] - Electrolyte drugs contributed 124 million CNY, 5.09% [3] Future Outlook - The company is optimistic about future growth, with a focus on becoming an international pharmaceutical technology company with strong profitability and innovation capabilities [4] - Management efficiency is improving, with sales expense ratio below 30%, management expense ratio at 5.30%, and financial expense ratio down by 82% [4][7] - Key products expected to drive growth include An Nao Wan/Pian, which saw sales of 182 million CNY in 2024, a growth of over 80% year-on-year [5] - The injection of multiple vitamins (12) is projected to maintain a market share of over 80% and achieve sales exceeding 1.1 billion CNY in 2024 [6][14] Cost Management - The company has successfully reduced sales, management, and financial expenses, with a continued focus on optimizing costs [7] - The financial expense ratio has decreased significantly, indicating effective cost control measures [7] Product Development and Partnerships - The company plans to introduce differentiated products in the short term, focusing on oral products and exclusive traditional Chinese medicine [9] - Collaboration with Daiichi Sankyo has expanded, contributing approximately 240 million CNY, or 10% of total revenue [11] - The company has over 20 projects in the pipeline, primarily focused on generic drugs [12] Shareholder Engagement - In 2024, the company executed a share buyback plan, utilizing approximately 80 million CNY to repurchase over 30 million shares [12] - The asset-liability ratio has decreased to 30%, with limited potential for further reduction in the short term [13]

Core Viewpoint - The company has disclosed its quarterly report, ensuring the accuracy and completeness of the financial information presented, and has not undergone an audit for this report [2][3][12]. Financial Data Summary - The company reported a fair value change gain of RMB 7.0927 million from its investment in WuXi Healthcare Ventures II, L.P. during Q1 2025 [5]. - The company completed a share buyback of 32,307,224 shares from March 10 to March 13, 2025, representing 1.42% of the total share capital, with a total expenditure of approximately RMB 79.99 million [8]. - The company has canceled and repurchased 1,653,000 restricted stocks from eight former employees who no longer meet the criteria for the 2024 restricted stock incentive plan [10]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders and the shareholding situation of the top ten shareholders were disclosed, with specific increases in holdings by certain private investment funds [6]. Important Events - The company held its first extraordinary general meeting of 2025 on February 6, 2025, resulting in an early board restructuring [7]. - The company’s potassium chloride oral solution received drug approval, enhancing its product offerings in the oral potassium supplement sector [11]. Legal Matters - The company is involved in a legal dispute with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) regarding an unpaid equity transfer payment of RMB 11.76 million, with the court ruling in favor of the company [9].

上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 李务所（特殊善通合伙） 关于哈尔滨誉衡药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2025)第 3922 号 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计 师审计准则要求我们遵循中国注册会计师职业道德守则,计划和执行审核工作对汇 总表是否不存在重大错报获取合理保证。在审核的过程中，我们实施了包括检查会 计记录、重新计算相关项目金额等我们认为必要的程序。我们相信,我们的审核工 作为发表审核意见提供了合理的基础。 事务所(特殊善通会 i Centified Public Secountants (Shecial General Partnership 哈尔滨誉衡药业股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表的 专项审核报告 上会师报字(2025)第 3922 号 哈尔滨誉衡药业股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了哈尔滨誉衡药业股份 有限公司（以下简称"贵公司"）2024 年度的财务报表，包括 2024 年 12 月 31 ...

哈尔滨誉衡药业股份有限公司 审计报告 上会师报字(2025)第 3876 号 上会会计师事务所（特殊普通合伙） 中国 上海 the state of the 计师 李 务所（特殊普通合 d Public Secountants (Shecial General Po 审计报告 上会师报字(2025)第 3876 号 哈尔滨誉衡药业股份有限公司全体股东: 一、审计意见 我们审计了哈尔滨誉衡药业股份有限公司(以下简称"誉衡药业")财务报表, 包括 2024 年 12 月 31 日的合并及母公司资产负债表, 2024年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报表 附注。 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于誉衡药业,并履行了职业道德方面的其 他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提供了 基础。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了誉衡药业 2024 年 ...

计师 事务所(特殊善通分 blic Scountants (Sheo 内部控制审计报告 上会师报字(2025)第 3879 号 哈尔滨誉衡药业股份有限公司全体股东; 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了哈尔滨誉衡药业股份有限公司(以下简称"贵公司")2024年12月31日的财 务报告内部控制的有效性。 哈尔滨誉衡药业股份有限公司 内部控制审计报告 上会师报字(2025)第 3879 号 上会会计师事务所（特殊普通合伙） 中国 上海 二、注册会计师的责任 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董事会 的责任。 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外，由于情 况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 据内部控制审计结果推测未来内部控制的有效性 ...

㈠ 个人工作履历、专业背景以及兼职情况 哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-041 哈尔滨誉衡药业股份有限公司 2024 年度独立董事述职报告 本人作为哈尔滨誉衡药业股份有限公司（以下简称"公司"）的第六届董事 会独立董事，严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以 及《公司章程》等相关规定，诚实、勤勉、独立地履行职责，切实发挥独立董事 作用。现将本人 2024 年度履行独立董事职责情况总结如下： 一、独立董事的基本情况 本人张晓丹，1975 年 9 月出生，中国国籍，本科学历。曾任国家药品监督 管理局职员，中信信托有限责任公司信托经理，凤凰医疗集团副总经理、总经理， 2022 年 12 月 20 日至 2025 年 2 月 6 日期间任公司独立董事。 ㈡ 是否存在影响独立性的情况说明 本人作为公司独立董事，符合《上市公司独立董事管理办法》对独立性的相 关要求，不存在影响独立性的任何情形。 二、独立董事年度履职概况 ㈠ 参加会议情况 本人积极参加公司召开的历次 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-040 哈尔滨誉衡药业股份有限公司 2024 年度独立董事述职报告 本人作为哈尔滨誉衡药业股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及《公司章程》 等相关规定，诚实、勤勉、独立地履行职责，及时了解公司发展状况，切实发挥 独立董事作用。现将本人 2024 年度履行独立董事职责情况总结如下： 一、独立董事的基本情况 ㈠ 个人工作履历、专业背景以及兼职情况 本人姜明辉，1978 年 11 月出生，中国国籍，硕士学历。曾任广东维摩律师 事务所、北京市安理（深圳）律师事务所合伙人律师。2022 年 12 月 20 日至 2024 年 5 月 10 日，任公司独立董事，担任公司独立董事期间，同时任职深圳市玩视 科技股份有限公司独立董事、上海申浩律师事务所合伙人律师。 ㈡ 是否存在影响独立性的情况说明 本人作为公司独立董事，符合《上市公司独立董事管理办法》对独立性的相 关要求，不存在影响独立性 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-039 哈尔滨誉衡药业股份有限公司 2024 年度独立董事述职报告 本人作为哈尔滨誉衡药业股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及《公司章程》 等相关规定，诚实、勤勉、独立地履行职责，及时了解公司发展状况，切实发挥 独立董事作用。现将本人 2024 年度履行独立董事职责情况总结如下： 一、独立董事的基本情况 ㈠ 个人工作履历、专业背景以及兼职情况 本人潘敏，1970 年 12 月出生，中国国籍，无境外永久居留权，研究生学历， 中国注册会计师、高级会计师。曾任陕西会计师事务所、陕西五联会计师事务所 经理、合伙人，万隆众天会计师事务所、万隆亚洲会计师事务所合伙人、信永中 和会计师事务所合伙人、天健会计师事务所合伙人。现任上海洪源投资控股有限 公司高级财务顾问、福建实达电脑设备有限公司董事、上海锦和商业经营管理股 份有限公司（603682）独立董事、江苏应能微电子股份有限公司独立董 ...